{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cejas RB"],"funding":["NCI NIH HHS"],"pagination":["115-134"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11260185"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64"],"pubmed_abstract":["Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional validation of AIC-associated variants in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to advance the implementation of genetic predictive biomarkers. Finally, we review how patient-specific hiPSC-CMs can be used to identify novel patient-relevant functional target"],"journal":["Annual review of pharmacology and toxicology"],"pubmed_title":["Anthracycline Toxicity: Light at the End of the Tunnel?"],"pmcid":["PMC11260185"],"funding_grant_id":["R01 CA220002"],"pubmed_authors":["Cejas RB","Sapkota Y","Burridge PW","Petrykey K"],"additional_accession":[]},"is_claimable":false,"name":"Anthracycline Toxicity: Light at the End of the Tunnel?","description":"Anthracycline-induced cardiotoxicity (AIC) is a serious and common side effect of anthracycline therapy. Identification of genes and genetic variants associated with AIC risk has clinical potential as a cardiotoxicity predictive tool and to allow the development of personalized therapies. In this review, we provide an overview of the function of known AIC genes identified by association studies and categorize them based on their mechanistic implication in AIC. We also discuss the importance of functional validation of AIC-associated variants in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to advance the implementation of genetic predictive biomarkers. Finally, we review how patient-specific hiPSC-CMs can be used to identify novel patient-relevant functional target","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-05-27T12:16:43.41Z","creation":"2025-04-03T23:36:17.573Z"},"accession":"S-EPMC11260185","cross_references":{"pubmed":["37788492"],"doi":["10.1146/annurev-pharmtox-022823-035521"]}}